^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    onvansertib (PCM-075) (PLK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation

    Excerpt:
    ...Kras mutation in exon 2, 3 or 4 in primary tumor or metastasis, assessed by a CLIA-certified lab. Subjects with concomitant Kras and BRAF-V600 utations are excluded from this study. Subjects with MSI-H/ddMMR (Microsatellite Instability High/Deficient Mismatch Repair) are also ineligible for enrollment in this study...
    Secondary therapy:
    FOLFIRI
    Trial ID:
    NCT03829410
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cardiff Oncology Press Release
    Title:

    Onvansertib Trial in KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across KRAS Mutation Subtypes and Durable Response

    Published date:
    04/28/2020
    Excerpt:
    Onvansertib Trial in KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across KRAS Mutation Subtypes and Durable Response….We are encouraged by the level of activity that we are observing with the combination of onvansertib and standard-of-care FOLFIRI and bevacizumab in our patients with KRAS-mutated colorectal cancer....As of the data cut-off date, clinical response was observed in 7 (88%) of the 8 evaluable patients.
    Secondary therapy:
    FOLFIRI
    Trial ID:
    NCT03829410